Animal Drugs Market to reach USD 82.5 billion By 2035
Published Date: June 12, 2026
Animal Drugs Market
The global animal drugs market was valued at USD 46.3 billion in 2025 and is expected to grow from USD 49.5 billion in 2026 to USD 82.5 billion in 2035, growing at a CAGR of 5.8% during the forecast period, as per the latest report published by Global Market Insights Inc.
Rising Prevalence of Animal Diseases
The increasing incidence of infectious, parasitic, and chronic diseases among livestock and companion animals is a major factor driving demand for animal health products and veterinary services. Growing animal populations, intensification of livestock farming, and increased movement of animals across regions have contributed to a higher risk of disease transmission.
Growing Focus on Livestock Productivity
Rising global demand for meat, milk, eggs, and other animal-derived products is encouraging producers to prioritize livestock productivity and overall herd health. Farmers are increasingly adopting advanced animal health solutions to improve growth rates, reproductive efficiency, feed conversion, and disease resistance. Enhanced productivity not only increases farm profitability but also helps meet the growing food requirements of expanding populations.
Adverse Side Effects and Drug Recalls
Despite the benefits of veterinary pharmaceuticals, concerns regarding adverse drug reactions and product recalls remain a significant challenge for industry. Certain medications may cause unintended side effects, including allergic reactions, toxicity, or reduced effectiveness in specific animal species or breeds. Such incidents can negatively impact animal health, reduce consumer confidence, and increase regulatory scrutiny.
Browse key industry insights spread across 270 pages with 316 market data tables and figures from the report, Animal Drugs Market , “By Product (Drugs, Vaccines, Medicated Feed Additives), By Indication (Dermatology, Cardiovascular Diseases, Gastrointestinal Diseases, Respiratory Diseases, Other Indications), By Animal Type (Companion Animals, Livestock Animals), By Route of Administration (Oral, Injectable, Topical, Other Routes of Administration), and By Distribution Channel (Veterinary Hospital Pharmacies, E-commerce, Retail Pharmacies). ” in detail, along with the table of contents:
https://www.gminsights.com/industry-analysis/animal-drugs-market
Drugs Segment Analysis
In 2025, the drugs segment accounted for USD 24.8 billion of the animal drugs market. The segment's strong position is attributed to the critical role veterinary pharmaceuticals play in the prevention and treatment of a wide range of animal health conditions. It includes antiparasitic, anti-inflammatory, anti-infective, and other therapeutic medications that are extensively used across livestock and companion animal healthcare.
Increasing Adoption Among Companion Animals
The companion animals segment accounted for 57.9% share in 2025. This segment includes dogs, cats, horses, and other companion animals. Market growth is primarily driven by the increasing adoption of pets across households worldwide and the growing emotional attachment between owners and their animals. Dogs and cats continue to represent the largest share of companion animal populations, contributing significantly to healthcare spending.
North America Animal Drugs Market Analysis
North America animal drugs industry held a 41.6% share in 2025. The region’s leadership is supported by high pet ownership rates, a well-developed veterinary healthcare ecosystem, and the strong presence of leading animal health companies. Growing expenditure on companion animal care, increasing prevalence of animal diseases, and favorable regulatory frameworks focused on animal health and welfare continue to support market expansion.
Major companies operating in the animal drugs market are Agrolabo S.p.A., Boehringer Ingelheim International, Ceva Santé Animale, Chanelle Pharma, Dechra Pharmaceuticals, Durvet Animal Health Products, Elanco Animal Health, Endovac Animal Health, HIPRA, Indian Immunologicals, Merck & Co., Inc., Neogen Corporation, Norbrook, Vetoquinol, Virbac, Zagro, and Zoetis.
Leading companies are focusing on expanding their veterinary pharmaceutical portfolios through continuous research and development of innovative drugs, vaccines, and preventive healthcare products. Strategic acquisitions, partnerships, and collaborations with veterinary clinics, distributors, and research institutions are helping companies strengthen their market reach and product offerings. Many players are investing in advanced biologics, specialty therapeutics, and companion animal healthcare solutions to address evolving market needs.
In September 2025, ZyVet Animal Health, a subsidiary of Zydus Pharmaceuticals USA Inc. and part of Zydus Lifesciences Ltd., unveiled two FDA- approved generic medicines for animals in the United States.